Innoviva (INVA) unit Innoviva Specialty Therapeutics said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.
The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.
Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.
Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.
The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。